I continue to see Roskamp, Archer and Michael Mullan as adversarial to all shareholders. There is no more Rock Creek and I don't see why it will ever emerge again. Therefore, the IP is up for bid and Archer/Mullan would like to get the rights for as little as possible. Ironically, Roskamp can continue to use anatabine because they are non-profit, but should they ever release positive results on GWI or TBI, it could increase perceived value of anatabine; which could increase bidding. Again not something Mullan would desire. All my opinion. What a true waste of such a great compound with all of this taking so long.
